Nanjing King-Friend Biochemical Pharmaceutical (603707.SH): Rocuronium Bromide Injection Obtains Drug Registration Certificate.
Jianniu Corporation (603707.SH) announced that the company recently received the approval for Rocuronium Bromide issued by the National Medical Products Administration.
Nanjing King-Friend Biochemical Pharmaceutical (603707.SH) announced that the company has recently received the drug registration certificate for Rocuronium Bromide Injection 5ml:50mg and 10ml:100mg issued by the National Medical Products Administration.
Rocuronium Bromide Injection is used as an adjuvant for general anesthesia, to facilitate tracheal intubation during routine induction of anesthesia, and to maintain neuromuscular blockade of skeletal muscles during surgery.
Related Articles
Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.
Industrial: Hong Kong stock market sentiment index has reached the bottom area.
"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.
Industrial: Hong Kong stock market sentiment index has reached the bottom area.
"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
RECOMMEND
Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026
Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026
Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026
